Signal or noise? > Ocugen's OCU410 gene therapy slows geographic atrophy lesion growth by up to 32% in Phase 2 - Dealroom >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharmaceutical #pharma